{"filing":{"accession_number":"0001140361-26-026982","cik":"0001281895","ticker":"RCKTW","company_name":"ROCKET PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"ef20077135_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126026982/ef20077135_8k.htm"},"events":[{"id":15015,"run_id":13395,"accession_number":"0001140361-26-026982","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses the appointment of Joseph Manhede as Principal Accounting Officer effective July 8, 2026, following the resignation of John Militello. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a named executive to a principal officer role (Principal Accounting Officer), making exec_appointment the most salient classification. The appointment of a Principal Accounting Officer is material to investors as it affects financial reporting oversight and internal controls.","company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKTW","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12624,"accession_number":"0001140361-26-026982","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Joseph Manhede as Principal Accounting Officer effective July 8, 2026, following the resignation of John Militello. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a named executive to a principal officer role (Principal Accounting Officer), making exec_appointment the most salient classification. The appointment of a Principal Accounting Officer is material to investors as it affects financial reporting oversight and internal controls.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:19:29.432859+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12624,"accession_number":"0001140361-26-026982","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Joseph Manhede as Principal Accounting Officer effective July 8, 2026, following the resignation of John Militello. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a named executive to a principal officer role (Principal Accounting Officer), making exec_appointment the most salient classification. The appointment of a Principal Accounting Officer is material to investors as it affects financial reporting oversight and internal controls.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:19:29.432859+00:00","company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKTW","filing_date":"2026-06-30"}]}